MTOR and fibrodysplasia ossificans progressiva: Recent therapeutic advancements for FOP encompass diverse therapeutic agents, including the RARγ agonist palovarotene (Chakkalakal et al, 2016; Lees-Shepard et al, 2018a), direct kinase inhibitors targeting BMP type I receptors’ catalytic domains (Engers et al, 2013; Hamasaki et al, 2012; Hao et al, 2010; Mohedas et al, 2013; Sanvitale et al, 2013; Yu et al, 2008), and neutralizing antibodies and inhibitors against Activin-A signaling and mTOR signaling (del Re et al, 2004; Hatsell et al, 2015; Hino et al, 2017; Hino et al, 2015; Sako et al, 2010; Souza et al, 2008).